Biological Activity
GSK-F1 is a potent inhibitor of PI4KA. It has markedly better pharmacokinetic properties in vivo with respects to GSK-A1 (SYN-1219). GSK-F1 does not cross the blood-brain barrier. Phosphatidylinositol 4-kinase type IIIα (PI4KA) is a host factor essential for hepatitis C virus replication and hence is a target for drug development. RNAi studies have shown that PI4KA is a mandatory host factor in HCV replication. Down-regulation of PI4KA appears to be reasonably tolerated by cultured cell models and results.
In Vitro
No in vitro data are provided in the current product source. Contact us for further information.
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.











